Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Solid Biosciences Inc is a drug manufacturers-specialty & generic business based in the US. Solid Biosciences shares (SLDB) are listed on the NASDAQ and all prices are listed in US Dollars. Solid Biosciences employs 121 staff and has a market cap (total outstanding shares value) of USD$211.6 million.
|Latest market close||USD$3.23|
|52-week range||USD$1.93 - USD$5.58|
|50-day moving average||USD$3.3721|
|200-day moving average||USD$2.9742|
|Wall St. target price||USD$4.7|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.796|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||2.87%|
|1 month (2020-11-06)||0.31%|
|3 months (2020-09-04)||49.54%|
|6 months (2020-06-04)||9.86%|
|1 year (2019-12-04)||-27.74%|
|2 years (2018-12-04)||-88.66%|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-71.05%|
|Return on equity TTM||-151.1%|
|Market capitalisation||USD$211.6 million|
TTM: trailing 12 months
There are currently 3.2 million Solid Biosciences shares held short by investors – that's known as Solid Biosciences's "short interest". This figure is 1% down from 3.2 million last month.
There are a few different ways that this level of interest in shorting Solid Biosciences shares can be evaluated.
Solid Biosciences's "short interest ratio" (SIR) is the quantity of Solid Biosciences shares currently shorted divided by the average quantity of Solid Biosciences shares traded daily (recently around 920770.77363897). Solid Biosciences's SIR currently stands at 3.49. In other words for every 100,000 Solid Biosciences shares traded daily on the market, roughly 3490 shares are currently held short.
However Solid Biosciences's short interest can also be evaluated against the total number of Solid Biosciences shares, or, against the total number of tradable Solid Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Solid Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Solid Biosciences shares in existence, roughly 50 shares are currently held short) or 0.0827% of the tradable shares (for every 100,000 tradable Solid Biosciences shares, roughly 83 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Solid Biosciences.
Find out more about how you can short Solid Biosciences stock.
We're not expecting Solid Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Solid Biosciences's shares have ranged in value from as little as $1.93 up to $5.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Solid Biosciences's is 0.8534. This would suggest that Solid Biosciences's shares are less volatile than average (for this exchange).
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.